Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

AstraZeneca Pares 7,300 Jobs; Ups China Spending

publication date: Feb 2, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AstraZeneca announced another 7,300 layoffs, bringing its total to over 21,000 over the past few years. The latest round will affect staff counts in the US and Europe. Among other things, the cutbacks mean closing the company’s in-house neuroscience R&D facilities, eliminating 2,200 staff and leaving AstraZeneca with a virtual program in that disease area. At the same time, AstraZeneca is building a $200 million plant in Taizhou; it has bought a generic drug company in China; and it recently signed a $140 million oncology drug partnership with Hutchison MediPharma. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...